News

Over the past decade, horizontal SaaS defined how we thought about software in life sciences: generic tools, per‑seat licenses, a focus on dashboards, and connecting users rather than deeply transforming workflows. With the 𝗿𝗶𝘀𝗲 𝗼𝗳 𝗔𝗜‑𝗻𝗮𝘁𝗶𝘃𝗲, 𝘃𝗲𝗿𝘁𝗶𝗰𝗮𝗹 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀, that paradigm is quietly shifting.

In 𝘀𝗽𝗮𝘁𝗶𝗮𝗹 𝗼𝗺𝗶𝗰𝘀, this shift is especially tangible. High‑plex imaging and complex multi‑modal data demand more than generic analytics dashboards or one‑off scripts. What labs and biopharma teams need are trustworthy, domain‑aware systems that help them interpret tissue architecture, spatial phenotypes, and biomarker patterns at scale, while fitting into real‑world translational and clinical R&D workflows.

At Katana Labs, we are building an AI‑native platform focused specifically on image analysis and data analytics for spatial omics. Our goal is not to replace scientists, but to augment them with robust, reproducible workflows, advanced models, and intuitive tools that make complex data more actionable. We work closely with partners to ensure that algorithms, QC, and reporting align with biological questions, study designs, and regulatory expectations rather than forcing teams into one‑size‑fits‑all software.

We are realistic about where the field is today, but 𝗴𝗲𝗻𝘂𝗶𝗻𝗲𝗹𝘆 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 about what this next wave of AI‑native, vertical platforms can unlock: more consistent analyses across sites, deeper biological insight from the same samples, and faster iteration between discovery, translational research, and clinical development. If we get this right as a community, spatial omics can move from “beautiful images” to a 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗹𝗮𝘆𝗲𝗿 𝗳𝗼𝗿 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗻𝗼𝘃𝗲𝗹 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀.

Image taken from Katana Edge platform.

Next week, Katana Labs will be represented at two important events bringing together innovators across biotech, biopharma, cancer research, translational oncology, and precision medicine: bio:cap in Berlin or EACR 2026 in Budapest.

We look forward to discussing how AI can advance our understanding of complex disease biology — especially how spatial tissue context can reveal cell behavior, tumor–immune interactions, niche organization, and molecular patterns that are critical for biomarker discovery and precision therapy development.

At Katana Labs, we are building Katana Edge, an AI-powered platform for spatial molecular profiling, spatial multiomics, and advanced tissue analysis. Our goal is to turn multidimensional data from scanned tissue samples into actionable insights that support biomarker discovery, translational research, and biopharma R&D.

Spatial biology is becoming a key technology for understanding cancer and other complex diseases — and we believe AI will be essential to make these datasets scalable, reproducible, and truly useful for research and drug development.

If you are attending bio:cap in Berlin or EACR 2026 in Budapest and are working on spatial biology, cancer research, biomarker discovery, translational oncology, or AI in precision medicine, we would be happy to connect and exchange ideas.

Katana Labs will be exhibiting at the 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝟐𝟎𝟐𝟔, taking place on 𝐌𝐚𝐲 𝟐𝟕–𝟐𝟖 𝐢𝐧 𝐑𝐨𝐭𝐭𝐞𝐫𝐝𝐚𝐦, 𝐓𝐡𝐞 𝐍𝐞𝐭𝐡𝐞𝐫𝐥𝐚𝐧𝐝𝐬. The congress brings together leading experts across spatial multiomics, computational tools for spatial data analysis, and applications of spatial biology in disease research and drug/biomarker development.

At the congress, we will showcase 𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞, our AI-native, cloud-based platform for 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐭𝐢𝐬𝐬𝐮𝐞 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 𝐚𝐭 𝐭𝐡𝐞 𝐬𝐢𝐧𝐠𝐥𝐞-𝐜𝐞𝐥𝐥 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐥𝐞𝐯𝐞𝐥.

With 𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞 and our associated services, R&D teams can easily and rapidly progress from complex spatial omics images to actionable biological insights through:
✔ Whole-slide image visualization and data management in a browser-based web application
✔ AI-powered image analysis, including automated QA/QC, WSI-wide cell segmentation, feature extraction, and much more
✔ Spatial biomarker analysis, automated clustering and cell phenotyping
✔ Standardized outputs for downstream analysis
✔ Collaborative end-to-end workflows and project management for globally operating R&D teams

𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐭𝐡𝐞 𝐝𝐚𝐭𝐚 𝐢𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞 𝐟𝐨𝐫 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐢𝐳𝐞𝐝 𝐚𝐧𝐝 𝐬𝐜𝐚𝐥𝐚𝐛𝐥𝐞 𝐀𝐈-𝐞𝐧𝐚𝐛𝐥𝐞𝐝 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐭𝐢𝐬𝐬𝐮𝐞 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠. By integrating image post-processing, cell segmentation, feature extraction, unsupervised clustering, cell phenotyping and spatial statistics into one well-structured image analysis workflow, Katana Edge creates the foundation for standardized spatial molecular profiling at scale. We offer hardware-agnostic consistency in results interpretation across projects and studies.

Walter de Back (CTO) and Luise Rupp (Product Specialist) are looking forward to meeting researchers from biopharma, CROs, spatial technology partners and academia in Rotterdam to demonstrate how spatial tissue profiling can accelerate your biomarker discovery, translational research, and drug development programs.

Katana Labs will be attending 𝐒𝐰𝐢𝐬𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐃𝐚𝐲 𝟐𝟎𝟐𝟔 𝐢𝐧 𝐁𝐚𝐬𝐞𝐥 𝐨𝐧 𝐌𝐚𝐲 𝟒–𝟓, organized by Swiss Biotech Association.
We look forward to connecting with stakeholders across biotech, biopharma, and CROs who are currently integrating spatial omics in their R&D workflows.

𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐨𝐦𝐢𝐜𝐬 is rapidly evolving from an exploratory technology into a 𝐜𝐨𝐫𝐞 𝐩𝐢𝐥𝐥𝐚𝐫 𝐨𝐟 𝐛𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐑&𝐃. R&D teams are increasingly leveraging spatial tissue profiling to:
✔ Enable patient stratification
✔ Drive drug and biomarker validation
✔ Decode the tumor microenvironment and immune response under treatment

At Katana Labs, we focus on transforming complex spatial omics datasets into 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐢𝐳𝐞𝐝, 𝐫𝐞𝐩𝐫𝐨𝐝𝐮𝐜𝐢𝐛𝐥𝐞, 𝐚𝐧𝐝 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧-𝐫𝐞𝐚𝐝𝐲 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐭 𝐬𝐜𝐚𝐥𝐞.

With our 𝐀𝐈-𝐩𝐨𝐰𝐞𝐫𝐞𝐝, 𝐜𝐥𝐨𝐮𝐝-𝐧𝐚𝐭𝐢𝐯𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞, combined with dedicated service offerings for biopharma, we enable R&D teams to integrate spatial tissue profiling and downstream data interpretation directly into their workflows.

If you feel the need to operationalize and standardize spatial omics in your R&D projects, talk to our 𝐂𝐄𝐎 𝐃𝐫. Norman Gerstner in Basel.

In collaboration with strong partners, Katana Labs leverages its images analysis, Deep Learning model development and software engineering expertise to push the limits in AI-enabled precision diagnostics. Together with Refined Laser Systems GmbH, Universitätsklinikum Carl Gustav Carus Dresden and Technische Universität Dresden, the German consortium initiated the 𝐊𝐔𝐑𝐄 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐩𝐫𝐨𝐣𝐞𝐜𝐭 to bring real-time, intraoperative histopathology-based tumor detection directly in the operating room.

The joint mission of this groundbreaking research study is to facilitate precise differentiation between healthy and cancerous tissue during surgery, thereby increasing the likelihood for successful tumor removal and reducing the overall time in surgery.

Today, confirming the successful surgical removal of all cancerous tissue often requires the dedicated histopathological analysis of samples in a pathology lab, including sample transport, preparation, staining, and expert review by one or more pathologists. This process takes time and often has to be repeated. During this histopathological analysis, the patient remains under anesthesia and the surgery is paused, limiting immediate decision-making by the responsible surgeon.

👉 𝐊𝐔𝐑𝐄 𝐚𝐢𝐦𝐬 𝐭𝐨 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐚𝐭:
Refined Laser Systems GmbH’ label-free SRS microscopy system generates high-resolution molecular images of fresh tissue directly at the point of care in the operation room.

At Katana Labs, we develop the 𝐀𝐈 𝐚𝐥𝐠𝐨𝐫𝐢𝐭𝐡𝐦𝐬, 𝐝𝐚𝐭𝐚 𝐢𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞, 𝐚𝐧𝐝 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐭𝐨 𝐚𝐧𝐚𝐥𝐲𝐳𝐞 𝐭𝐡𝐢𝐬 𝐥𝐚𝐛𝐞𝐥-𝐟𝐫𝐞𝐞 𝐢𝐦𝐚𝐠𝐢𝐧𝐠 𝐝𝐚𝐭𝐚 𝐢𝐧 𝐫𝐞𝐚𝐥 𝐭𝐢𝐦𝐞. We train the AI models to automatically detect tumor regions in distinction to healthy tissue and provide structured, interpretable outputs that support surgeons and pathologists in decision-making during surgery.

𝐓𝐡𝐞 𝐠𝐨𝐚𝐥𝐬:
✔ Immediate identification of cancerous tissue directly during surgery
✔ AI-assisted decision support to inform the surgeon/pathologist with real-time histopathology data
✔ Proof-of-principle for developing a scalable framework for broader applications in cancer surgery

The KURE project is funded by the Bundesministerium für Bildung und Forschung under the 𝐊𝐈𝐎𝐧 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐦𝐞, supporting AI innovations in healthcare.

Our technical team is expanding with Marcelo Leomil Zoccoler joining as our newest member. 🙌

His expertise in 𝐌𝐋-𝐛𝐚𝐬𝐞𝐝 𝐛𝐢𝐨-𝐢𝐦𝐚𝐠𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 will be pivotal in integrating 𝐧𝐞𝐱𝐭-𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐬 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 and ensuring a reliable SaaS experience for our users. He will coordinate key custom projects that deliver direct value to clients while helping expand Katana Edge’s feature set.

Marcelo has a proven track record of successfully resolving complex image analysis challenges in close collaboration with R&D teams. He has a strong ability to translate cutting-edge research and user needs from academia, biopharma, and CROs into effective analytical solutions.

𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞 𝘪𝘴 𝘢𝘯 𝘈𝘐 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮 𝘧𝘰𝘳 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘴𝘱𝘢𝘵𝘪𝘢𝘭 𝘵𝘪𝘴𝘴𝘶𝘦 𝘱𝘳𝘰𝘧𝘪𝘭𝘪𝘯𝘨. 𝘐𝘵 𝘴𝘦𝘢𝘮𝘭𝘦𝘴𝘴𝘭𝘺 𝘪𝘯𝘵𝘦𝘨𝘳𝘢𝘵𝘦𝘴 𝘮𝘶𝘭𝘵𝘪𝘰𝘮𝘪𝘤𝘴, 𝘴𝘱𝘢𝘵𝘪𝘢𝘭 𝘣𝘪𝘰𝘭𝘰𝘨𝘺, 𝘢𝘯𝘥 𝘴𝘪𝘯𝘨𝘭𝘦-𝘤𝘦𝘭𝘭 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘪𝘯𝘵𝘰 𝘰𝘯𝘦 𝘤𝘰𝘯𝘷𝘦𝘯𝘪𝘦𝘯𝘵 𝘤𝘭𝘰𝘶𝘥 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮.

In biopharma R&D and at CROs, spatial omics has become a core pillar for 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲, 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐚𝐧𝐝 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐭𝐢𝐬𝐬𝐮𝐞 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 𝐟𝐨𝐫 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐬𝐭𝐮𝐝𝐢𝐞𝐬. R&D teams routinely generate large numbers of high-dimensional multiplex tissue images across large cohorts, aiming to extract robust spatial biomarkers and further data that can guide drug development and patient stratification.

The challenge is no longer data generation, it’s turning complex spatial image data into 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐢𝐳𝐞𝐝, 𝐫𝐞𝐩𝐫𝐨𝐝𝐮𝐜𝐢𝐛𝐥𝐞, 𝐚𝐧𝐝 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧-𝐫𝐞𝐚𝐝𝐲 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐭 𝐬𝐜𝐚𝐥𝐞.

With our 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐨𝐦𝐢𝐜𝐬 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 and our AI-based and cloud-native 𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦, R&D teams in biopharma and at CROs can move from multiplex tissue images to standardized, decision-ready insight generations and spatial biomarker outputs 𝐟𝐚𝐬𝐭, 𝐫𝐞𝐩𝐫𝐨𝐝𝐮𝐜𝐢𝐛𝐥𝐞, 𝐚𝐧𝐝 𝐬𝐜𝐚𝐥𝐚𝐛𝐥𝐞.

Focus on the biology and study outcomes and let Katana Labs handle the heavy IT and analytics part.

Katana Labs 𝐨𝐟𝐟𝐞𝐫𝐬:
🎯 𝐀𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐬𝐢𝐧𝐠𝐥𝐞-𝐜𝐞𝐥𝐥 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 for complex mIF tissues
🎯 𝐂𝐨𝐡𝐨𝐫𝐭-𝐬𝐜𝐚𝐥𝐞 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐢𝐧𝐠 across WSIs and TMAs
🎯 𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐟𝐞𝐚𝐭𝐮𝐫𝐞 𝐞𝐱𝐭𝐫𝐚𝐜𝐭𝐢𝐨𝐧 at single-cell and sub-cellular resolution
🎯 𝐁𝐮𝐢𝐥𝐭-𝐢𝐧 𝐐𝐀/𝐐𝐂 and customized reports for confident interpretation

If you need robust spatial biomarker outputs for translational or clinical studies, contact us via Scientist.com profile or at services@katana-labs.com.

Spatial omics provides unparalleled insights into tissue organization, cellular interactions, and molecular disease mechanisms by preserving the native tissue architecture of biopsy samples from solid tumors. 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 tissue sections on the 𝐬𝐜𝐚𝐥𝐞 𝐨𝐟 𝐦𝐢𝐥𝐥𝐢𝐦𝐞𝐭𝐞𝐫𝐬 𝐰𝐡𝐢𝐥𝐞 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧𝐢𝐧𝐠 𝐬𝐢𝐧𝐠𝐥𝐞-𝐜𝐞𝐥𝐥 𝐫𝐞𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 makes the complex interactions between cancer cells, healthy cells, and the tumor microenvironment visible and 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥𝐥𝐲 𝐚𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐥𝐞.

With rapid advances in spatial proteomics and spatial transcriptomics, tissue images are becoming larger and more complex than ever before. Today, whole-slide images often contain 𝐦𝐢𝐥𝐥𝐢𝐨𝐧𝐬 𝐨𝐟 𝐜𝐞𝐥𝐥𝐬 𝐩𝐞𝐫 𝐭𝐢𝐬𝐬𝐮𝐞 𝐬𝐞𝐜𝐭𝐢𝐨𝐧, pushing existing analysis tools to their limits.

🚀 𝐓𝐡𝐢𝐬 𝐢𝐬 𝐰𝐡𝐞𝐫𝐞 𝐨𝐮𝐫 𝐀𝐈-𝐧𝐚𝐭𝐢𝐯𝐞 𝐜𝐥𝐨𝐮𝐝 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝘒𝘢𝘵𝘢𝘯𝘢 𝘌𝘥𝘨𝘦 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐭𝐡𝐞 𝐝𝐚𝐭𝐚 𝐢𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞 𝐟𝐨𝐫 𝐬𝐜𝐚𝐥𝐚𝐛𝐥𝐞 𝐰𝐡𝐨𝐥𝐞-𝐬𝐥𝐢𝐝𝐞 𝐢𝐦𝐚𝐠𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬, 𝐞𝐚𝐬𝐢𝐥𝐲 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐬 𝐰𝐞𝐛 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧.

With our latest 𝘒𝘢𝘵𝘢𝘯𝘢 𝘌𝘥𝘨𝘦 𝐮𝐩𝐝𝐚𝐭𝐞, you now can 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 >𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐜𝐞𝐥𝐥𝐬 𝐢𝐧 𝐚 𝐬𝐢𝐧𝐠𝐥𝐞 𝐭𝐢𝐬𝐬𝐮𝐞 𝐬𝐞𝐜𝐭𝐢𝐨𝐧, 𝐪𝐮𝐚𝐧𝐭𝐢𝐟𝐲 >𝟖𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐩𝐚𝐫𝐚𝐦𝐞𝐭𝐞𝐫𝐬 (markers, shape, and spatial features), and view the results in an interactive map 𝐯𝐢𝐚 𝐨𝐮𝐫 𝐛𝐫𝐨𝐰𝐬𝐞𝐫-𝐛𝐚𝐬𝐞𝐝 𝐢𝐧𝐭𝐞𝐫𝐟𝐚𝐜𝐞 𝐟𝐨𝐫 𝐯𝐢𝐬𝐮𝐚𝐥 𝐞𝐱𝐩𝐥𝐨𝐫𝐚𝐭𝐢𝐨𝐧.

There is no requirement for on-premise compute infrastructure or complex IT setups. We deliver scalable, high-performance spatial biology analysis as a readily available SaaS product. 𝘒𝘢𝘵𝘢𝘯𝘢 𝘌𝘥𝘨𝘦 handles spatial omics files in the 𝐆𝐁/𝐓𝐁 𝐫𝐚𝐧𝐠𝐞 𝐞𝐚𝐬𝐢𝐥𝐲, providing the data infrastructure to accelerate spatial tissue profiling, biomarker discovery and patient stratification.

🔬 If you are interested to easily 𝐚𝐧𝐚𝐥𝐲𝐳𝐞 𝐲𝐨𝐮𝐫 𝐰𝐡𝐨𝐥𝐞-𝐬𝐥𝐢𝐝𝐞 𝐢𝐦𝐚𝐠𝐞𝐬 𝐚𝐜𝐫𝐨𝐬𝐬 𝐬𝐜𝐚𝐥𝐞𝐬 and streamline your spatial omics R&D projects, reach out to us. We’re happy to demo the 𝘒𝘢𝘵𝘢𝘯𝘢 𝘌𝘥𝘨𝘦 platform and offer a trial phase using your own sample data.

As we enter the new year, Katana Labs moves into its 𝐧𝐞𝐱𝐭 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐜𝐡𝐚𝐩𝐭𝐞𝐫.

After two years of focused product development, successful market entry, team growth, and serving our first customers, we are ready to scale – transitioning from pilot engagements to full commercial growth.

🚀 To lead this next phase, we are pleased to announce that Dr. Norman Gerstner will assume the role of 𝐂𝐄𝐎 𝐚𝐬 𝐨𝐟 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟔. Norman joined Katana Labs in 2025 to spearhead our marketing and sales efforts during the market entry phase. With nearly two decades of experience across DeepTech, life sciences, and precision oncology, he brings a 𝐬𝐭𝐫𝐨𝐧𝐠 𝐭𝐫𝐚𝐜𝐤 𝐫𝐞𝐜𝐨𝐫𝐝 in commercial execution and strategic leadership.

The whole Katana Labs team is deeply grateful to Falk Zakrzewski, Nicolaus Widera and Walter de Back for building the strong technological and cultural foundation we stand on today.

Our founders and investors are confident that Katana Labs will unlock its full potential under Norman’s leadership as we scale our platform, expand our customer footprint and establish the company as an 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐩𝐥𝐚𝐲𝐞𝐫 𝐢𝐧 𝐭𝐡𝐞 𝐓𝐞𝐜𝐡𝐁𝐢𝐨 𝐬𝐞𝐜𝐭𝐨𝐫.

𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐭𝐢𝐬𝐬𝐮𝐞 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 is rapidly reshaping the precision medicine value chain – from translational research and clinical development to improving clinical trial outcomes.

At Katana Labs, we build the data infrastructure and AI/ML tools that make deeply embedded, actionable insights in biological tissue samples accessible across biological scales and at enterprise level. Alongside our B2B enterprise SaaS platform 𝐊𝐚𝐭𝐚𝐧𝐚 𝐄𝐝𝐠𝐞, we provide expert services in image analysis and data analytics for spatial biology and spatial multi-omics.

✨ Founders, investors, and the entire team are excited to enter this 𝐧𝐞𝐱𝐭 𝐠𝐫𝐨𝐰𝐭𝐡 𝐩𝐡𝐚𝐬𝐞 𝐨𝐟 𝐊𝐚𝐭𝐚𝐧𝐚 𝐋𝐚𝐛𝐬.

Katana Labs now offers its 𝐀𝐈-𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 via Scientist.com. For R&D teams in CROs, clinical research, and biopharma it is now easy to access our 𝐢𝐦𝐚𝐠𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐝𝐚𝐭𝐚 𝐚𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐬 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 via this trusted procurement platform.

Katana Labs provides advanced image analysis and data analytics services for 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐛𝐢𝐨𝐥𝐨𝐠𝐲, 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐨𝐦𝐢𝐜𝐬 𝐚𝐧𝐝 𝐭𝐢𝐬𝐬𝐮𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬, including histopathology and computational pathology.

With 𝟏𝟎+ 𝐲𝐞𝐚𝐫𝐬 𝐨𝐟 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 in computer vision, machine learning/deep learning, data science, bioinformatics, computational biology, and developing purpose-built algorithms for automated image analysis, we are well positioned to support your tissue omics workflows.

By combining cutting-edge AI with deep domain knowledge in life sciences, translational research and precision oncology, we empower 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬 to extract, quantify, and interpret the biological information and multidimensional data deeply embedded in tissue samples.

🔬 𝐎𝐮𝐫 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
✔️Accurate cell segmentation on mIF whole slide images (no limitation in channels, markers, cells)
✔️ Batch image analysis at scale
✔️ Biomarker quantification and feature extraction
✔️ QA/QC and workflow validation
✔️ End-to-end spatial omics data analytics
✔️ Access to the data in various formats for further processing and analysis

📊 𝐒𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝 𝐦𝐨𝐝𝐚𝐥𝐢𝐭𝐢𝐞𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
Multiplex immunofluorescence (mIF), spatial proteomics (highplex & hyperplex IF), spatial transcriptomics, FISH, IHC, and related imaging workflows.

🧪 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐬𝐞𝐫𝐯𝐢𝐜𝐞 𝐜𝐚𝐭𝐞𝐠𝐨𝐫𝐢𝐞𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
Automated Image Analysis • Digital Pathology • Bioinformatics • Discovery Biomarker Analytics • Histopathology • Immunohistochemistry • FISH • Multi-Omics Studies • Single-Cell Services • Tissue Microarrays • Marker Analyses and more.

From study design to final data delivery, we provide 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞, 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐚𝐜𝐫𝐨𝐬𝐬 𝐭𝐡𝐞 𝐞𝐧𝐭𝐢𝐫𝐞 𝐢𝐦𝐚𝐠𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐝𝐚𝐭𝐚 𝐚𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐬 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞.

👉 If you’re looking for a trusted and experienced partner to outsource your spatial biology and spatial omics image analysis projects, we are happy to support you via Scientist.com.